Revenio Group Oyj — Director's Dealing 2018

Jun 27, 2018

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Managers' transactions, July 27, 2017 at 14:20

Revenio Group Corporation: Managers' transactions

Revenio Group Oyj - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Timo Hilden
Position: Chief Executive Officer
(X) Legal person
Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20180627095558_2
____________________________________________

Transaction date: 2018-06-26
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009010912
Nature of the transaction: EXERCISE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 1,000 Unit price: 17.7 EUR
(2): Volume: 1,000 Unit price: 17.7 EUR

Aggregated transactions
(2): Volume: 2,000 Volume weighted average price: 17.7 EUR

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:
Nasdaq Helsinki
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.

[]